Ad-hoc | 12 May 2005 11:11

bmp AG: bmp acquires majority of Revotar AG

Ad hoc announcement §15 WpHG Investment bmp AG: bmp acquires majority of Revotar AG Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Berlin, 12 May 2005 Following a subscription for shares in Revotar Biopharmaceuticals AG and within the framework of a financing round and the accompanying reorganisation of the shareholders, bmp announces today that it has taken the opportunity to significantly increase its stake in Revotar Biopharmaceuticals AG, the most important biotechnology holding in its portfolio, from 22.4% to 59.96%. Revotar has very propitious clinical phase II data on psoriasis and asthma. Another phase II pilot study on COPD (chronic bronchitis) is also currently underway. Thus the company has an extremely promising product pipeline in strong-growing blockbuster markets and is one of the few biotech companies with positive clinical phase II results. The financial means made available within the framework of the capital increase will aid further clinical development as well as the establishment of partnerships with the biotechnology and/or pharmaceuitcals industry. The company is aiming to achieve a trade sale or IPO within the next two to three years. Contact: Corinna Riewe criewe@bmp.com bmp AG Alt-Moabit 59-61 10555 Berlin Deutschland ISIN: DE0003304200 WKN: 330420 Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, München und Stuttgart; Warschau End of ad hoc announcement (c)DGAP 12.05.2005 121111 Mai 05